HTLV-1 Associated Myelopathy
Symptoms, Doctors, Treatments, Advances & More

HTLV-1 Associated Myelopathy Overview

Save information for later
Sign Up

Learn About HTLV-1 Associated Myelopathy

What is the definition of HTLV-1 Associated Myelopathy?
HTLV-1 associated myelopathy/tropical spastic paraparesis (HAM/TSP) is a progressive disease of the nervous system that affects less than 2% of people with HTLV-1 infection. Signs and symptoms vary but may include slowly progressive weakness and spasticity of one or both legs, exaggerated reflexes, muscle contractions in the ankle, and lower back pain. Other features may include urinary incontinence and minor sensory changes, especially burning or prickling sensations and loss of vibration sense. The reason some people with HTLV-1 infection develop HAM/TSTP is not well understood.
What are the alternative names for HTLV-1 Associated Myelopathy?
  • HTLV-1 associated myelopathy/tropical spastic paraparesis
  • HAM/TSP
  • Human T-cell leukemia virus type 1 associated myelopathy/tropical spastic paraparesis
  • Tropical spastic paraparesis (formerly)
Who are the top HTLV-1 Associated Myelopathy Local Doctors?
Elite in HTLV-1 Associated Myelopathy
Elite in HTLV-1 Associated Myelopathy
Referral may be required
St. Marianna University School Of Medicine, 
Kawasaki, JP 

Yoshihisa Yamano practices practicing medicine in Kawasaki, Japan. Yamano is rated as an Elite expert by MediFind in the treatment of HTLV-1 Associated Myelopathy. They are also highly rated in 9 other conditions, according to our data. Their clinical expertise encompasses HTLV-1 Associated Myelopathy, Spastic Paraparesis, Myelitis, Thalamotomy, and Thrombectomy.

Elite in HTLV-1 Associated Myelopathy
Elite in HTLV-1 Associated Myelopathy
Referral may be required
St. Marianna University School Of Medicine, 
Kanagawa, JP 

Tomoo Sato practices practicing medicine in Kanagawa, Japan. Sato is rated as an Elite expert by MediFind in the treatment of HTLV-1 Associated Myelopathy. They are also highly rated in 5 other conditions, according to our data. Their clinical expertise encompasses HTLV-1 Associated Myelopathy, Spastic Paraparesis, Myelitis, and Adult T-Cell Leukemia.

 
 
 
 
Learn about our expert tiers
Learn More
Elite in HTLV-1 Associated Myelopathy
Elite in HTLV-1 Associated Myelopathy
Referral may be required
St. Marianna University School Of Medicine, 
Kanagawa, JP 

Natsumi Araya practices practicing medicine in Kanagawa, Japan. Ms. Araya is rated as an Elite expert by MediFind in the treatment of HTLV-1 Associated Myelopathy. She is also highly rated in 5 other conditions, according to our data. Her clinical expertise encompasses HTLV-1 Associated Myelopathy, Spastic Paraparesis, Myelitis, and Adult T-Cell Leukemia.

View All Doctors
What are the latest HTLV-1 Associated Myelopathy Clinical Trials?
Immuno-Virological Evaluation of Human T Cell Leukemia Virus Type-1 Associated Myelopathy (HAM/TSP)
Immuno-Virological Evaluation of Human T Cell Leukemia Virus Type-1 Associated Myelopathy (HAM/TSP)
Enrollment Status: Recruiting
Publish Date: June 18, 2026

Objective: Human T-lymphotropic virus type-I-associated myelopathy / tropical spastic paraparesis (HAM/TSP) is a rare neurologic disorder that affects less than 5% of patients infected with the HTLV-I virus. The purpose of this protocol is to study the natural history of HAM/TSP by monitoring clinical progression of patients longitudinally. Additionally, we will attempt to define the virological and immunolo...

Match to trials
Find the right clinical trials for you in under a minute
Get started
Dolutegravir Versus Dolutegravir in Combination With Tenofovir for the Treatment of HTLV-1 Infection (DOT-H): an Open-label, Randomized, Controlled Study.
Dolutegravir Versus Dolutegravir in Combination With Tenofovir for the Treatment of HTLV-1 Infection (DOT-H): an Open-label, Randomized, Controlled Study.
Enrollment Status: Recruiting
Publish Date: June 02, 2026
Intervention Type: Combination product, Drug
Study Phase: Phase 2

Summary: This phase 2b, open-label, randomized controlled trial evaluates the efficacy and safety of dolutegravir (DTG) alone versus dolutegravir combined with tenofovir disoproxil fumarate (TDF) in individuals with HTLV-1 infection and associated clinical manifestations. The primary objective is to compare changes in HTLV-1 proviral load at 24 and 48 weeks. Secondary outcomes include clinical, functional,...

View All Clinical Trials
Who are the sources who wrote this article ?

Published Date: May 02, 2022
Published By: Genetic and Rare Diseases Informnation Center